C-type lectin-like receptor-2 (CLEC-2) is a key regulator of kappa-carrageenan-induced tail thrombosis model in mice
In this study, we investigated the molecular basis of KCG-induced platelet activation using light-transmittance aggregometry, flow cytometry, western blotting, and surface plasmon resonance assays using platelets from platelet receptor-deficient mice and recombinant proteins. KCG-induced tail thrombosis was also evaluated in mice lacking the platelet receptor. We found that KCG induces platelet aggregation with α-granule secretion, activated integrin αIIbβ3, and phosphatidylserine exposure. As this aggregation was significantly inhibited by the Src family kinase inhibitor and spleen tyrosine kinase (Syk) inhibitor, a ty...
Source: Platelets - November 27, 2023 Category: Hematology Authors: Ryohei Yokomori Toshiaki Shirai Nagaharu Tsukiji Saori Oishi Tomoyuki Sasaki Katsuhiro Takano Katsue Suzuki-Inoue Source Type: research
Cryopreservation affects platelet macromolecular composition over time after thawing and differently impacts on cancer cells behavior in vitro
Platelets. 2023 Dec;34(1):2281943. doi: 10.1080/09537104.2023.2281943. Epub 2023 Nov 27.ABSTRACTCryopreservation affects platelets' function, questioning their use for cancer patients. We aimed to investigate the biochemical events that occur over time after thawing to optimize transfusion timing and evaluate the effect of platelet supernatants on tumor cell behavior in vitro. We compared fresh (Fresh-PLT) with Cryopreserved platelets (Cryo-PLT) at 1 h, 3 h and 6 h after thawing. MCF-7 and HL-60 cells were cultured with Fresh- or 1 h Cryo-PLT supernatants to investigate cell proliferation, migration, and PLT-cell adhesion....
Source: Platelets - November 27, 2023 Category: Hematology Authors: Gaia Gavioli Agnese Razzoli Diana E Bedolla Erminia Di Bartolomeo Eleonora Quartieri Barbara Iotti Pamela Berni Giovanni Birarda Lisa Vaccari Davide Schiroli Chiara Marraccini Roberto Baricchi Lucia Merolle Source Type: research
C-type lectin-like receptor-2 (CLEC-2) is a key regulator of kappa-carrageenan-induced tail thrombosis model in mice
In this study, we investigated the molecular basis of KCG-induced platelet activation using light-transmittance aggregometry, flow cytometry, western blotting, and surface plasmon resonance assays using platelets from platelet receptor-deficient mice and recombinant proteins. KCG-induced tail thrombosis was also evaluated in mice lacking the platelet receptor. We found that KCG induces platelet aggregation with α-granule secretion, activated integrin αIIbβ3, and phosphatidylserine exposure. As this aggregation was significantly inhibited by the Src family kinase inhibitor and spleen tyrosine kinase (Syk) inhibitor, a ty...
Source: Platelets - November 27, 2023 Category: Hematology Authors: Ryohei Yokomori Toshiaki Shirai Nagaharu Tsukiji Saori Oishi Tomoyuki Sasaki Katsuhiro Takano Katsue Suzuki-Inoue Source Type: research
Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8.ABSTRACTThe conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO. The total effective rate of...
Source: Platelets - November 9, 2023 Category: Hematology Authors: Xiuli Wang Hui Bi Lin Liu Yuebo Liu Liefen Yin Jin Yao Jingxing Yu Wei Tao Yueping Wei Yu Li Lingmei Yin Hongli Mu Yadong Du Zeping Zhou Source Type: research
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
Platelets. 2023 Dec;34(1):2276697. doi: 10.1080/09537104.2023.2276697. Epub 2023 Nov 9.NO ABSTRACTPMID:37941443 | DOI:10.1080/09537104.2023.2276697 (Source: Platelets)
Source: Platelets - November 9, 2023 Category: Hematology Authors: Hiroyuki Kimura Masahiro Onozawa Takanori Teshima Source Type: research
Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8.ABSTRACTThe conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO. The total effective rate of...
Source: Platelets - November 9, 2023 Category: Hematology Authors: Xiuli Wang Hui Bi Lin Liu Yuebo Liu Liefen Yin Jin Yao Jingxing Yu Wei Tao Yueping Wei Yu Li Lingmei Yin Hongli Mu Yadong Du Zeping Zhou Source Type: research
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
Platelets. 2023 Dec;34(1):2276697. doi: 10.1080/09537104.2023.2276697. Epub 2023 Nov 9.NO ABSTRACTPMID:37941443 | DOI:10.1080/09537104.2023.2276697 (Source: Platelets)
Source: Platelets - November 9, 2023 Category: Hematology Authors: Hiroyuki Kimura Masahiro Onozawa Takanori Teshima Source Type: research
Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8.ABSTRACTThe conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO. The total effective rate of...
Source: Platelets - November 9, 2023 Category: Hematology Authors: Xiuli Wang Hui Bi Lin Liu Yuebo Liu Liefen Yin Jin Yao Jingxing Yu Wei Tao Yueping Wei Yu Li Lingmei Yin Hongli Mu Yadong Du Zeping Zhou Source Type: research
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
Platelets. 2023 Dec;34(1):2276697. doi: 10.1080/09537104.2023.2276697. Epub 2023 Nov 9.NO ABSTRACTPMID:37941443 | DOI:10.1080/09537104.2023.2276697 (Source: Platelets)
Source: Platelets - November 9, 2023 Category: Hematology Authors: Hiroyuki Kimura Masahiro Onozawa Takanori Teshima Source Type: research
Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8.ABSTRACTThe conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO. The total effective rate of...
Source: Platelets - November 9, 2023 Category: Hematology Authors: Xiuli Wang Hui Bi Lin Liu Yuebo Liu Liefen Yin Jin Yao Jingxing Yu Wei Tao Yueping Wei Yu Li Lingmei Yin Hongli Mu Yadong Du Zeping Zhou Source Type: research
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
Platelets. 2023 Dec;34(1):2276697. doi: 10.1080/09537104.2023.2276697. Epub 2023 Nov 9.NO ABSTRACTPMID:37941443 | DOI:10.1080/09537104.2023.2276697 (Source: Platelets)
Source: Platelets - November 9, 2023 Category: Hematology Authors: Hiroyuki Kimura Masahiro Onozawa Takanori Teshima Source Type: research
Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8.ABSTRACTThe conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO. The total effective rate of...
Source: Platelets - November 9, 2023 Category: Hematology Authors: Xiuli Wang Hui Bi Lin Liu Yuebo Liu Liefen Yin Jin Yao Jingxing Yu Wei Tao Yueping Wei Yu Li Lingmei Yin Hongli Mu Yadong Du Zeping Zhou Source Type: research
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
Platelets. 2023 Dec;34(1):2276697. doi: 10.1080/09537104.2023.2276697. Epub 2023 Nov 9.NO ABSTRACTPMID:37941443 | DOI:10.1080/09537104.2023.2276697 (Source: Platelets)
Source: Platelets - November 9, 2023 Category: Hematology Authors: Hiroyuki Kimura Masahiro Onozawa Takanori Teshima Source Type: research
Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8.ABSTRACTThe conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO. The total effective rate of...
Source: Platelets - November 9, 2023 Category: Hematology Authors: Xiuli Wang Hui Bi Lin Liu Yuebo Liu Liefen Yin Jin Yao Jingxing Yu Wei Tao Yueping Wei Yu Li Lingmei Yin Hongli Mu Yadong Du Zeping Zhou Source Type: research
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans
Platelets. 2023 Dec;34(1):2276697. doi: 10.1080/09537104.2023.2276697. Epub 2023 Nov 9.NO ABSTRACTPMID:37941443 | DOI:10.1080/09537104.2023.2276697 (Source: Platelets)
Source: Platelets - November 9, 2023 Category: Hematology Authors: Hiroyuki Kimura Masahiro Onozawa Takanori Teshima Source Type: research
